Ballys (NYSE:BALY) reported quarterly sales of $547.70 million which missed the analyst consensus estimate of $580.78 million by 5.70 percent. This is a 363.78 percent increase over sales of $118.10 million the same period last year.
Lilly-Boehringer Partnered Jardiance Slows Kidney Disease Progression, Data Shows
Boehringer Ingelheim and Eli Lilly And Co (NYSE:LLY) said their diabetes drug Jardiance showed to slow the progression of chronic kidney disease.…